KR20230043227A - 일주기 리듬 수면 장애를 치료하는 방법 - Google Patents

일주기 리듬 수면 장애를 치료하는 방법 Download PDF

Info

Publication number
KR20230043227A
KR20230043227A KR1020237009013A KR20237009013A KR20230043227A KR 20230043227 A KR20230043227 A KR 20230043227A KR 1020237009013 A KR1020237009013 A KR 1020237009013A KR 20237009013 A KR20237009013 A KR 20237009013A KR 20230043227 A KR20230043227 A KR 20230043227A
Authority
KR
South Korea
Prior art keywords
sleep
pharmaceutical composition
composition according
subject
subject experiences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237009013A
Other languages
English (en)
Korean (ko)
Inventor
카스텐 티. 뷰크만
마가렛 몰린
앤드류 사틀린
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20230043227A publication Critical patent/KR20230043227A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237009013A 2016-05-12 2017-05-11 일주기 리듬 수면 장애를 치료하는 방법 Ceased KR20230043227A (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201662335611P 2016-05-12 2016-05-12
US201662335599P 2016-05-12 2016-05-12
US62/335,611 2016-05-12
US62/335,599 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US62/413,976 2016-10-27
US201662414599P 2016-10-28 2016-10-28
US201662414606P 2016-10-28 2016-10-28
US62/414,606 2016-10-28
US62/414,599 2016-10-28
KR1020187035708A KR102511855B1 (ko) 2016-05-12 2017-05-11 일주기 리듬 수면 장애를 치료하는 방법
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187035708A Division KR102511855B1 (ko) 2016-05-12 2017-05-11 일주기 리듬 수면 장애를 치료하는 방법

Publications (1)

Publication Number Publication Date
KR20230043227A true KR20230043227A (ko) 2023-03-30

Family

ID=58745465

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237009013A Ceased KR20230043227A (ko) 2016-05-12 2017-05-11 일주기 리듬 수면 장애를 치료하는 방법
KR1020187035708A Active KR102511855B1 (ko) 2016-05-12 2017-05-11 일주기 리듬 수면 장애를 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187035708A Active KR102511855B1 (ko) 2016-05-12 2017-05-11 일주기 리듬 수면 장애를 치료하는 방법

Country Status (16)

Country Link
US (2) US11096941B2 (enExample)
EP (2) EP3454859B1 (enExample)
JP (2) JP6888026B2 (enExample)
KR (2) KR20230043227A (enExample)
CN (1) CN109640998A (enExample)
AU (3) AU2017264871B2 (enExample)
CA (1) CA3022068A1 (enExample)
ES (1) ES2904625T3 (enExample)
IL (2) IL291791B2 (enExample)
MX (1) MX379318B (enExample)
MY (1) MY199382A (enExample)
RU (1) RU2763493C2 (enExample)
SG (1) SG11201809527UA (enExample)
TW (1) TWI795359B (enExample)
WO (1) WO2017197160A1 (enExample)
ZA (1) ZA201807903B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2763493C2 (ru) * 2016-05-12 2021-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы лечения расстройств циркадного ритма сна
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
CA3144067A1 (en) * 2019-06-26 2020-12-30 Eisai R&D Management Co., Ltd. Lemborexant for treating sleep issues
CA3151634A1 (en) * 2019-09-13 2021-03-18 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating insomnia
EP4073058A1 (en) * 2019-12-11 2022-10-19 Teva Czech Industries s.r.o. Solid state form of lemborexant
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
EP4376954A1 (en) * 2021-07-26 2024-06-05 Eisai R&D Management Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
CA3266968A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases
CN121646412A (zh) 2023-08-08 2026-03-10 株式会社明治 昼夜节律的调整

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556753C (en) * 2004-02-20 2014-11-25 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
MY160969A (en) 2010-09-22 2017-03-31 Eisai R&D Man Co Ltd Cyclopropane compounds
RU2014136339A (ru) * 2012-02-07 2016-03-27 Иолас Терапьютикс, Инк. Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов
MX376164B (es) * 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
RU2763493C2 (ru) * 2016-05-12 2021-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы лечения расстройств циркадного ритма сна

Also Published As

Publication number Publication date
EP3454859A1 (en) 2019-03-20
KR20190013820A (ko) 2019-02-11
MX2018013663A (es) 2019-07-18
ZA201807903B (en) 2021-04-28
CA3022068A1 (en) 2017-11-16
EP3454859B1 (en) 2021-12-01
TWI795359B (zh) 2023-03-11
US20210353625A1 (en) 2021-11-18
MY199382A (en) 2023-10-25
US20200179382A1 (en) 2020-06-11
MX379318B (es) 2025-03-10
TW201740952A (zh) 2017-12-01
IL262803A (en) 2018-12-31
IL291791A (en) 2022-06-01
NZ748555A (en) 2025-06-27
RU2018143809A3 (enExample) 2020-09-17
RU2018143809A (ru) 2020-06-15
JP2021120410A (ja) 2021-08-19
AU2017264871B2 (en) 2023-03-16
IL262803B (en) 2022-05-01
KR102511855B1 (ko) 2023-03-20
AU2017264871A1 (en) 2018-11-15
IL291791B1 (en) 2025-05-01
WO2017197160A1 (en) 2017-11-16
ES2904625T3 (es) 2022-04-05
US11096941B2 (en) 2021-08-24
IL291791B2 (en) 2025-09-01
BR112018073037A2 (pt) 2019-02-26
JP7150096B2 (ja) 2022-10-07
SG11201809527UA (en) 2018-11-29
EP4056180A1 (en) 2022-09-14
JP2019518732A (ja) 2019-07-04
AU2025205336A1 (en) 2025-07-31
JP6888026B2 (ja) 2021-06-16
CN109640998A (zh) 2019-04-16
AU2023203418A1 (en) 2023-06-29
RU2763493C2 (ru) 2021-12-29

Similar Documents

Publication Publication Date Title
KR102511855B1 (ko) 일주기 리듬 수면 장애를 치료하는 방법
US20230293506A1 (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
Lee et al. A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma
CA3083341C (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
HK40007283A (en) Methods of treating circadian rhythm sleep disorders
NZ787958A (en) Methods of treating circadian rhythm sleep disorders
WO2020264201A1 (en) Lemborexant for treating sleep issues
BR122024003210A2 (pt) Uso de um composto
US20250064802A1 (en) Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
BR112018073037B1 (pt) Uso de um composto
IL303006A (en) Use of pyridofidine and analogues for the treatment of Rett syndrome
EP3989976A1 (en) Lemborexant for treating sleep issues
WO2020263331A1 (en) Lemborexant for treating sleep issues
JP2026508357A (ja) 脊髄性筋萎縮症を処置するための組成物及び方法
Kamath Study of Anticonvulsant Effect of Simvastatin in Maximal Electroshock and Pentylenetetrazole Induced Seizure Model in Albino Mice
Conen et al. CNS impairing effects of hydroxyzine as a function of histamine

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230315

Application number text: 1020187035708

Filing date: 20181210

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230706

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240110

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230706

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20240110

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20231106

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20240620

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20240610

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20240110

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20231106

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20230706

X601 Decision of rejection after re-examination